Gain Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Gain Therapeutics, Inc. (Nasdaq: GANX) is a clinical-stage biotechnology company focused on discovering and developing a novel class of allosteric small molecule therapies. The company utilizes its proprietary, in-licensed computational drug discovery platform, Magellan™, to identify novel allosteric binding sites on disease-implicated proteins. By targeting these sites, Gain designs brain-penetrant small molecules that correct protein misfolding and restore or modulate protein function, addressing the underlying causes of severe neurodegenerative, lysosomal storage, and metabolic disorders. Its lead clinical candidate is GT-02287, an orally administered, brain-penetrant allosteric enzyme modulator designed to restore the function of the lysosomal enzyme glucocerebrosidase (GCase). This pathway is highly relevant for Parkinson's disease patients with or without GBA1 gene mutations.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead drug candidate, GT-02287, an oral, brain-penetrant allosteric GCase modulator, through clinical trials for the treatment of Parkinson's disease with or without GBA1 mutations.
Expected impact: Establish clinical proof-of-concept and disease-modifying potential by restoring GCase function, reducing toxic substrates, and slowing Parkinson's disease progression.
Utilizing the proprietary Magellan platform, which integrates AI, physics-based supercomputing, and 3D structure modeling, to identify novel allosteric binding sites and develop small molecule candidates for undruggable targets.
Expected impact: Generate a steady pipeline of first-in-class allosteric modulators targeting neurodegenerative diseases, lysosomal storage disorders, metabolic diseases, and oncology.
Actively exploring strategic partnerships, licensing agreements, and academic collaborations to co-develop pipeline assets and secure non-dilutive funding.
Expected impact: Extend the company's financial runway beyond Q1 2027 and accelerate late-stage clinical development timelines through pharmaceutical industry partnerships.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides critical non-dilutive funding and scientific validation for the development of GT-02287 in Parkinson's disease.
Terms: Grant funding support (specific financial terms not disclosed).
Supports preclinical and clinical research targeting GBA1-associated Parkinson's disease, aligning with Gain's lead program.
Terms: Grant funding support (specific financial terms not disclosed).
Supports the discovery and development of novel allosteric modulators using the Magellan platform.
Terms: Grant funding support (specific financial terms not disclosed).